Do you want to contribute to a future without dementia with Lewy bodies? Apply now.
Contribute to a future without dementia with Lewy bodies
What we’ve achieved so far
75
Trials
500
Participants
3
Locations
Our dementia with Lewy bodies trials
RewinD-LB
RewinD-LB
The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug are capsules that you take with food.
55+
Dementia with Lewy bodies
Study days are spread over 21 to 55 weeks
Amsterdam, Den Bosch or Zwolle
Contact us
Do you have questions, or would you like to know more about one of our studies? Contact us by telephone or email. We are happy to help you.
